Study drug
petechiae, platelet aggregation, Ramos
PETECHIAE, SUBCUTANEOUS HAEMORRHAGE
TAS5315 selectively inhibited BTK enzyme activity and suppressed anti-IgM antibody induced phosphorylation of BTK in Ramos cells.Phase 1 studies showed TAS5315 was tolerable when administered as repeated doses of up to 8 mg once daily for 7 days, although inhibition of platelet aggregation was observed and a small proportion of individuals developed mild subcutaneous haemorrhage and petechiae.